UY35001A - Formulación de comprimidos compuestos de dos fases que comprende atorvastatina, irbesartan y carbonato de magnesio - Google Patents

Formulación de comprimidos compuestos de dos fases que comprende atorvastatina, irbesartan y carbonato de magnesio

Info

Publication number
UY35001A
UY35001A UY0001035001A UY35001A UY35001A UY 35001 A UY35001 A UY 35001A UY 0001035001 A UY0001035001 A UY 0001035001A UY 35001 A UY35001 A UY 35001A UY 35001 A UY35001 A UY 35001A
Authority
UY
Uruguay
Prior art keywords
formulation
irbesartan
magnesium carbonate
phase composite
phase
Prior art date
Application number
UY0001035001A
Other languages
English (en)
Spanish (es)
Inventor
Jae Hyun Park
Jong Soo Woo
Yong Ii Kim
Jung Hyun Cho
Jun Young Choi
Young Keun Choi
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50183917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35001(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of UY35001A publication Critical patent/UY35001A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
UY0001035001A 2012-08-31 2013-08-30 Formulación de comprimidos compuestos de dos fases que comprende atorvastatina, irbesartan y carbonato de magnesio UY35001A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120096477A KR20140028971A (ko) 2012-08-31 2012-08-31 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제

Publications (1)

Publication Number Publication Date
UY35001A true UY35001A (es) 2014-03-31

Family

ID=50183917

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035001A UY35001A (es) 2012-08-31 2013-08-30 Formulación de comprimidos compuestos de dos fases que comprende atorvastatina, irbesartan y carbonato de magnesio

Country Status (31)

Country Link
US (1) US20150209290A1 (enExample)
EP (1) EP2890368A4 (enExample)
JP (1) JP6363079B2 (enExample)
KR (1) KR20140028971A (enExample)
CN (1) CN104602677A (enExample)
AR (1) AR092386A1 (enExample)
AU (1) AU2013309686B2 (enExample)
BR (1) BR112015004471A8 (enExample)
CA (1) CA2882735A1 (enExample)
CL (1) CL2015000402A1 (enExample)
CR (1) CR20150115A (enExample)
DO (1) DOP2015000040A (enExample)
EA (1) EA030306B1 (enExample)
EC (1) ECSP15010600A (enExample)
GT (1) GT201500043A (enExample)
IL (1) IL237424A0 (enExample)
IN (1) IN2015DN01463A (enExample)
MA (1) MA37951B2 (enExample)
MX (1) MX354800B (enExample)
MY (1) MY175897A (enExample)
NI (1) NI201500027A (enExample)
NZ (1) NZ706472A (enExample)
PE (1) PE20150935A1 (enExample)
PH (1) PH12015500394A1 (enExample)
RU (1) RU2015111546A (enExample)
SG (1) SG11201500584YA (enExample)
TW (1) TWI651101B (enExample)
UA (1) UA115995C2 (enExample)
UY (1) UY35001A (enExample)
WO (1) WO2014035188A1 (enExample)
ZA (1) ZA201502156B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6981088B2 (ja) * 2017-01-27 2021-12-15 ニプロ株式会社 経口固形製剤
AU2018301924B2 (en) * 2017-07-17 2021-07-29 Eli Lilly And Company Pharmaceutical compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
US20030114497A1 (en) 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra
KR101230731B1 (ko) * 2008-04-29 2013-02-07 한올바이오파마주식회사 약제학적 제제
WO2011121824A1 (ja) * 2010-03-29 2011-10-06 アステラス製薬株式会社 口腔内崩壊錠
KR101248804B1 (ko) 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제

Also Published As

Publication number Publication date
GT201500043A (es) 2017-08-24
US20150209290A1 (en) 2015-07-30
JP2015530384A (ja) 2015-10-15
MX2015002526A (es) 2015-06-23
ECSP15010600A (es) 2015-12-31
EP2890368A4 (en) 2016-03-02
KR20140028971A (ko) 2014-03-10
CL2015000402A1 (es) 2015-06-05
PE20150935A1 (es) 2015-06-20
NZ706472A (en) 2018-02-23
TW201414507A (zh) 2014-04-16
UA115995C2 (uk) 2018-01-25
BR112015004471A8 (pt) 2019-08-27
BR112015004471A2 (pt) 2017-07-04
AU2013309686A1 (en) 2015-02-26
IN2015DN01463A (enExample) 2015-07-03
MA37951B2 (fr) 2019-12-31
CA2882735A1 (en) 2014-03-06
EP2890368A1 (en) 2015-07-08
DOP2015000040A (es) 2015-04-15
ZA201502156B (en) 2016-07-27
AU2013309686B2 (en) 2017-09-07
JP6363079B2 (ja) 2018-07-25
RU2015111546A (ru) 2016-10-20
WO2014035188A1 (en) 2014-03-06
CN104602677A (zh) 2015-05-06
SG11201500584YA (en) 2015-02-27
AR092386A1 (es) 2015-04-22
NI201500027A (es) 2017-01-04
MY175897A (en) 2020-07-14
CR20150115A (es) 2015-04-16
MA37951A1 (fr) 2018-06-29
PH12015500394A1 (en) 2015-04-27
EA030306B1 (ru) 2018-07-31
EA201590469A1 (ru) 2015-06-30
IL237424A0 (en) 2015-04-30
MX354800B (es) 2018-03-22
TWI651101B (zh) 2019-02-21

Similar Documents

Publication Publication Date Title
DOP2012000264A (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
CR20190204A (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
FI3256218T3 (fi) Kdm1a-estäjät sairauksien hoidossa
NI201400108A (es) Compuestos de heterociclilo
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
CL2014002986A1 (es) Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k.
PH12015501554A1 (en) Sustained-release lipid pre-concentrate of anionic pharmacologically active substances and pharmaceutical composition comprising the same
TR201902057T4 (tr) Tetrasiklin bileşikleri.
ECSP15010617A (es) Formulación de una cápsula farmacéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa campo de la invención
UY33348A (es) Compuestos de furopiridina y usos de los mismos
MX2016004021A (es) Composicion medica que contiene un inhibidor para absorcion de colesterol y un inhibidor para la biosintesis de colesterol.
MX374106B (es) Una composicion farmaceutica que contiene candesartan cilexetilo y amlodipina.
DOP2015000040A (es) Formulación de comprimidos compuestos de dos fases que comprende atorvastatina, irbesartan y carbonato de magnesio
HRP20151340T1 (hr) Derivati tieno[2,3-d] pirimidina i njihova primjena u lijeäśenju aritmije
HRP20171514T1 (hr) Derivati indolouree supstituirani glukopiranozilom i njihova upotreba kao inhibitora sglt
ES2436344B1 (es) Composición farmacéutica de diacetilmorfina y naloxona para administración oral
UY36958A (es) Compuestos para administración intracelular
TR201005911A2 (tr) Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210602